Our collective appetite for weight loss drugs has become pretty much insatiable over the past few years. It’s thought that around 1.5 million people in the UK are on GLP-1 agonist medications to curb their appetites, while over in the US, around 12 per cent of the population have used them for weight loss.
The Wegovy or Mounjaro pen stored in the fridge alongside a (presumably diminished) grocery shop has become the defining image of the so-called “skinny jab” era, with users self-administering weekly injections. But in 2026, that’s about to change. Soon, GLP-1 users will instead be able to reach for a daily pill that promises all of the advantages of the jab, without having to brave the needle. It’s a step forward that could drastically shake up an already booming market.
